ResApp Health Ltd (ASX: RAP) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

ResApp Health Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $43.82 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 859.20 million
Earnings per share -0.009
Dividend per share N/A
Year To Date Return -10.77%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

ResApp Health Ltd (ASX: RAP)
Latest News

Businessman outside jumps in the air
Healthcare Shares

ResApp (ASX:RAP) share price jumps 5% on regulatory approval

The ResApp Health Ltd (ASX: RAP) share price ticked up a notch towards the end of Monday’s market session. This followed the …

Read more »

Jumbo Interactive staffers shaking hands around table agreeing to an acquisition
Healthcare Shares

ResApp (ASX:RAP) share price rockets 11% on new Johnson & Johnson deal

The ResApp Health Ltd (ASX: RAP) share price is soaring during early afternoon trade on Thursday. This comes after the digital health …

Read more »

rising medical asx share price represented by excited doctors dancing in ward
Share Market News

ResApp (ASX:RAP) share price adds 4% on COVID-19 study rebate

The ResApp Health Ltd (ASX: RAP) share price is on the move again today following yesterday’s meteoric rise. The digital health company …

Read more »

doctor and nurse smiling in a hospital ward representing rising share price
52-Week Highs

ResApp (ASX:RAP) share price races 18% higher today, up 65% in a week

The ResApp Health Ltd (ASX: RAP) share price has been trending among investors, following its meteoric rise in recent memory. At the …

Read more »

three excited doctors with hands in the air
Healthcare Shares

Why the ResApp (ASX:RAP) share price is flying 25% higher today

The ResApp Health Ltd (ASX: RAP) share price is flying higher today, up 25%. The company – which provides health …

Read more »

ehealth
Healthcare Shares

ResApp (ASX:RAP) share price surges 5% on new agreement

The ResApp Health Ltd (ASX: RAP) share price is racing higher in mid-morning trade. This comes after the company announced …

Read more »

Thumbs down Facebook icon over dark screen
Capital Raising

Why the ResApp (ASX:RAP) share price is down 9% today

The ResApp Health Ltd (ASX: RAP) share price has returned from its trading halt and sunk lower. At the time …

Read more »

white arrow pointing down
Share Fallers

Why Corp Travel Management, IGO, Limeade, & ResApp are tumbling lower

The S&P/ASX 200 Index (ASX: XJO) is out of form on Wednesday and sinking lower. In afternoon trade, the benchmark index …

Read more »

RAP ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About ResApp Health Ltd

ResApp Health Ltd is engaged in development and commercialization of the ResApp technology for the purpose of providing health care solutions for respiratory disease. The company's solutions are designed to be easily integrated into existing telehealth solutions and it is working on apps to provide respiratory disease diagnosis and management directly to consumers and healthcare providers. Its products are for Acute Disease Diagnosis; for Chronic Disease Management; and for Sleep Apnoea.

RAP Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
27 Jan 2022 $0.05 $-0.01 -17.24% 3,087,132 $0.06 $0.06 $0.05
25 Jan 2022 $0.06 $0.00 0.00% 359,270 $0.06 $0.06 $0.06
24 Jan 2022 $0.06 $0.00 0.00% 649,145 $0.06 $0.06 $0.06
21 Jan 2022 $0.06 $0.00 0.00% 335,834 $0.06 $0.06 $0.06
20 Jan 2022 $0.06 $0.00 0.00% 202,747 $0.06 $0.06 $0.06
19 Jan 2022 $0.06 $0.00 0.00% 678,770 $0.06 $0.06 $0.06
18 Jan 2022 $0.06 $0.00 0.00% 677,196 $0.06 $0.06 $0.06
17 Jan 2022 $0.06 $0.00 0.00% 290,448 $0.06 $0.06 $0.06
14 Jan 2022 $0.06 $-0.01 -15.38% 867,613 $0.07 $0.07 $0.06
13 Jan 2022 $0.07 $0.01 16.67% 3,606,314 $0.06 $0.07 $0.06
12 Jan 2022 $0.06 $0.00 0.00% 402,198 $0.06 $0.06 $0.06
11 Jan 2022 $0.06 $0.00 0.00% 2,634,692 $0.06 $0.06 $0.06
10 Jan 2022 $0.06 $0.00 0.00% 755,641 $0.06 $0.06 $0.06
07 Jan 2022 $0.06 $0.00 0.00% 963,458 $0.06 $0.06 $0.06
06 Jan 2022 $0.06 $0.00 0.00% 692,540 $0.06 $0.06 $0.06
05 Jan 2022 $0.06 $0.00 0.00% 341,842 $0.06 $0.06 $0.06
04 Jan 2022 $0.07 $0.00 0.00% 771,336 $0.07 $0.07 $0.06
31 Dec 2021 $0.07 $0.00 0.00% 636,191 $0.06 $0.07 $0.06
30 Dec 2021 $0.06 $0.00 0.00% 753,083 $0.06 $0.06 $0.06

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
15 Mar 2021 Roger Aston Buy 290 $20,300
On-market trade.
15 Mar 2021 Christopher Ntoumenopoulos Buy 500 $35,500
On-market trade.
15 Mar 2021 Anthony (Tony) Keating Buy 225 $16,200
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Roger Aston Non-Executive ChairmanNon-Executive Director Jul 2015
Dr Aston is a scientist and seasoned biotechnology entrepreneur. He has been closely involved in start-up companies and major pharmaceutical companies. Aspects of his experience include US Food and Drug Administration (FDA) and European Union (EU) product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors. Dr Aston has also held Directorships/Chairmanships with Clinuvel Ltd, HalcyGen Ltd, and Ascent Pharma Ltd, was a member of the AusIndustry Biological Committee advising the Industry Research and Development Board. More recently, Dr Aston was Executive Chairman of Mayne Pharma Group from 2009 to 2011 and later, CEO of Mayne Pharma Group.
Dr Michael Stein Non-Executive Director Apr 2020
Dr Stein is currently acting CEO of immuno-oncology company, Valo Therapeutics. Immediately prior to Valo, he was the founding CEO of OxStem Ltd, an award-winning biotechnology spinout from the University of Oxford. Dr Stein previously served as founding CEO for Doctor Care Anywhere, a UK-based telemedicine platform acquired by Synergix in 2015. In 2001, he cofounded the Map of Medicine with University College London and was founding CEO. The Map was a set of clinical algorithms that represented the patient healthcare journey from suspected diagnosis to treatment across all healthcare settings. The Map was nationally licensed across NHS England and was acquired by Hearst Business Media in 2008.
Mr Brian Willoughby Leedman Executive Director Corporate Affairs May 2021
Mr Leedman is a marketing and investor relations professional with over 15 years' experience in the biotechnology industry. Mr Leedman is the founder of ResApp Diagnostics Pty Ltd which was acquired by Narhex Life Sciences Ltd to form ResApp Health. Prior to ResApp, Mr Leedman co-founded Oncosil Medical Limited and Biolife Science (QLD) Limited (acquired by Imugene Limited). Mr Leedman previously served for 10 years as Vice President, Investor Relations for pSivida Corp which is listed on the ASX and NASDAQ. He is formerly the WA chairman of AusBiotech, the association of biotechnology companies in Australia.
Mr Christopher Ntoumenopoulos Non-Executive Director Jan 2015
Mr Ntoumenopoulos is the Managing Director of Twenty 1 Corporate. He has worked in financial markets for the past 15 years, focusing on Capital Raisings, Portfolio Management and Corporate Advisory. Mr Ntoumenopoulos has advised and funded numerous ASX companies from early stage venture capital, through to IPO. He is an executive director of various private companies which span across finance, technology and medical sectors.
Dr Anthony (Tony) Keating Chief Executive OfficerManaging Director Jul 2015
Dr Keating has over ten years' experience in commercialising technology. Dr Keating created the initial business strategy for ResApp and has led the commercialization of ResApp's technology to date. Previously, Dr Keating was Director, Commercial Engagement at UniQuest Pty Ltd, one of the global leaders in commercialisation of university technology. While at UniQuest, Dr Keating held roles as interim Chief Executive Officer and Non-Executive Director for a number of privately-held, venture-capital funded start-up companies. Prior to joining UniQuest Dr Keating held business development and engineering management roles at Exa Corporation, a US-based software company that was listed on the NASDAQ and later acquired by Dassault Systemes.
Ms Nicki Farley Company Secretary
-
Nicki Farley Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 92,778,638 10.80%
Freeman Road Pty Ltd <The Avenue A/C> 35,850,000 4.17%
Sunreef Pty Ltd <Great Wall A/C> 19,749,751 2.30%
Mr Frank Weng Thong Chew 16,278,000 1.89%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <DRP A/C> 14,303,550 1.66%
Mr Anthony James Keating 10,225,000 1.19%
Hunter Capital Advisors P/L 9,000,000 1.05%
Equimetrixs Pty Ltd <The Newtonmore Superannuation Fund> 8,437,500 0.98%
Narhex Life Sciences Developments Pty Ltd 7,997,005 0.93%
CEM International (Asia) Pty Ltd 7,849,888 0.91%
Mr Yongsheng Peng & Mrs Yuezhen Xie 7,069,771 0.82%
BNP Paribas Nominees Pty Ltd <IB AU Noms Retail Client DRP> 6,254,951 0.73%
Queensland Forest Industries Pty Ltd 5,750,000 0.67%
Paranji Super Fund Pty Ltd <Paranji Superfund A/C> 5,285,000 0.62%
Citicorp Nominees Pty Limited 5,193,549 0.60%
Mr Victor John Wilk 4,400,000 0.51%
Mr Trent Antony Goodrick 4,250,000 0.49%
Mr Xiaoyi Lin 4,000,000 0.47%
Wilk Holdings Pty Ltd <Wilk Superannuation Fund A/C> 4,000,000 0.47%
Dr Geoffrey Waring 3,750,764 0.44%

Profile

since

Note